Dr. Jerry T. Thornthwaite received his bachelor's degree in chemistry from Lipscomb University in Nashville, Tennessee, and his MS and PhD in chemistry/biophysics from Florida State University in Tallahassee, FL. In 1972, he discovered what is now recognized as the Natural Killer Cells (NKCs), the cornerstone of our surveillance defense mechanism against the survival of cancer- and viral-infected cells. In 1977, he discovered what are now called cancer stem cells (CSCs). We are developing ways to increase NKCs and inhibit CSCs. In 1980, he found that a simple DNA measurement in breast cancer tissue could predict survival, thus prescribing the treatment of cancer patients. Based on his translational research, he established the two largest Immuno-oncology laboratories in Miami at Cedars Medical Center and Baptist Hospital, serving as the licensed clinical director of these Pathology departments. In 2003, he identified an IgM antibody to a unique 16mer polypeptide that was used to detect a variety of cancers early and to monitor them by tracking the rise and fall of IgM levels. He and his wife, Bonita, conducted medical mission trips to Haiti over a 12-year period, where he developed a cure for malaria in 2017. To date, in collaboration with MiVital AG, he created the NutraNanoSphere (NNS) application to boost NKCs, inhibit CSCs, treat babies with Malaria, and further treat cognitive, autoimmune, and heart diseases.  He has over 60 publications and 10 patents.  He currently directs cancer research at the Cancer Research Institute in Henderson and serves as Chief Scientist at Protocol.com in Dallas.